{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:44:41Z","timestamp":1769723081016,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.xjidi.2021.100025","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T13:23:06Z","timestamp":1620307386000},"page":"100025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6783-1904","authenticated-orcid":false,"given":"Clinton W.","family":"Enos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4999-0458","authenticated-orcid":false,"given":"Katie A.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4575-006X","authenticated-orcid":false,"given":"Ryan W.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5352-3794","authenticated-orcid":false,"given":"Robert R.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0056-997X","authenticated-orcid":false,"given":"Blessing","family":"Dube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3863-3842","authenticated-orcid":false,"given":"Abby S.","family":"Van Voorhees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2021.100025_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis","volume":"76","author":"Armstrong","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100025_bib2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.amepre.2010.12.019","article-title":"Geographic distribution of diagnosed diabetes in the U.S.: a diabetes belt","volume":"40","author":"Barker","year":"2011","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.xjidi.2021.100025_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2105\/AJPH.55.5.673","article-title":"Changes and geographic distribution of mortality from cerebrovascular disease","volume":"55","author":"Borhani","year":"1965","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.xjidi.2021.100025_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.17219\/acem\/69804","article-title":"The reliability of three psoriasis assessment tools: psoriasis area and severity index, body surface area and physician global assessment","volume":"26","author":"Bo\u017cek","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.xjidi.2021.100025_bib5","first-page":"1119","article-title":"Geographic variations in biologic therapy and disease characteristics: a pilot-study in the Corrona Psoriasis Registry","volume":"19","author":"Enos","year":"2020","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.xjidi.2021.100025_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/j.xjidi.2021.100025_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/2475530318781308","article-title":"Prescription pattern variability of biologic therapies in treating psoriasis","volume":"3","author":"Galli","year":"2018","journal-title":"J\u00a0Psoriasis Psoriatic Arthritis"},{"key":"10.1016\/j.xjidi.2021.100025_bib8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.0022-202x.2001.01656.x","article-title":"HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features","volume":"118","author":"Gu\u00f0j\u00f3nsson","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2021.100025_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41387-018-0024-2","article-title":"Geographical variation in the prevalence of obesity, metabolic syndrome, and diabetes among US adults","volume":"8","author":"Gurka","year":"2018","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.xjidi.2021.100025_bib10","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/rheumatology\/kew326","article-title":"The influence of obesity on response to tumour necrosis\u00a0factor-alpha inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries","volume":"55","author":"H\u00f8jgaard","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.xjidi.2021.100025_bib11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jaad.2009.11.012","article-title":"Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations","volume":"63","author":"Lebwohl","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100025_bib12","first-page":"848","article-title":"A\u00a0comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies","volume":"13","author":"Levin","year":"2014","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.xjidi.2021.100025_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/biomet\/73.1.13","article-title":"Longitudinal data analysis using generalized linear models","volume":"73","author":"Liang","year":"1986","journal-title":"Biometrika"},{"key":"10.1016\/j.xjidi.2021.100025_bib14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100025_bib15","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jaad.2019.10.014","article-title":"Where you live matters: regional differences in health care resource use for psoriasis in the United States","volume":"82","author":"Nguyen","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100025_bib17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2021.100025_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","article-title":"Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis","volume":"86","author":"Shan","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.xjidi.2021.100025_bib19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40291-019-00423-z","article-title":"HLA correlations with clinical phenotypes and risk of metabolic comorbidities in Singapore Chinese psoriasis patients","volume":"23","author":"Shen","year":"2019","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.xjidi.2021.100025_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.xjidi.2021.100025_bib21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","article-title":"Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry","volume":"78","author":"Strober","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026721000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026721000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:59:51Z","timestamp":1763020791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026721000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2667026721000254"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2021.100025","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2021.100025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100025"}}